The authorization follows positive results from an ongoing late-stage clinical trial, which demonstrated a meaningful reduction in proteinuria among patients. While the drug is already established as a treatment for several other rare conditions, this expansion specifically targets the underlying symptoms of IgAN.

Because the approval is granted on an accelerated basis, AstraZeneca remains committed to verifying long-term clinical benefits as the study progresses. Future access to the market for this specific indication may depend on the final data collected from these ongoing trials.